retatrutide clinical trials review vs Ozempic: Trial Comparisons Retatrutide Safety, Side Effects &

Mechanism: How the Glucagon Receptor Changes Everything The key mechanistic distinction in the triple agonist vs dual agonist debate is the glucagon receptor (GCGR)

GLP-1 medications such as semaglutide and tirzepatide are injected under the skin (subcutaneous), not into muscle

doi: 10.1074/jbc.272.7.4108 85 KoltermanOGKimDDShenLRugglesJANielsenLLFinemanMSet al

Glucagon Receptor Engagement : The addition of glucagon receptor activation is the core feature that separates Retatrutide from dual-agonist compounds

These medications have demonstrated significant weight loss (5-22%) and metabolic benefits in rigorous clinical trials when prescribed and monitored by healthcare providers

Thus, BED appears to involve GLP-1 dysregulation without consistent endocrine abnormalities, implying that GLP-1 RA therapy works through supraphysiological receptor activation and modulation of central reward circuitry, rather than by correcting a hormonal deficit [55]